

# Q-PLEX™ SARS-CoV-2 HUMAN IgG (5-PLEX)




The Q-Plex™ SARS-CoV-2 Human IgG (5-Plex) array simultaneously recognizes human IgG antibodies to S1 and S2 subunits of the spike glycoprotein as well as antibodies specific for the nucleocapsid protein (NP).

**QUANSYS**   
BIOSCIENCES

# Principle of the Assay

The Q-Plex™ SARS-CoV-2 Human IgG (5-Plex) array simultaneously recognizes human IgG antibodies to S1 and S2 subunits of the spike glycoprotein as well as antibodies specific for the nucleocapsid protein (NP). Whereas the spike glycoprotein is crucial for the virus' ability to attach to a cell, the NP is the primary protein that makes up the shell, or capsid, of the virus. The assay also detects antibodies towards the Fc region of sheep antibody to control for cross-reactivity between sample and the assay components. Finally, the kit uses detection of anti-human IgG as a positive control to ensure the assay performs to expectations.



Analyte	Assay Type	Calibrator Range	Upper Limit of Quantification (ULOQ)	Lower Limit of Quantification (LLOQ)	Limit of Detection	Precision (Inter-assay)	Precision (Intra-assay)	Average Linearity
SARS-CoV-2 S1	Indirect	1,000 - 1.37 (U/mL)	700 (U/mL)	5.50 (U/mL)	0.69 (U/mL)	10%	9%	107%
SARS-CoV-2 S2	Indirect	1,000 - 1.37 (U/mL)	700 (U/mL)	5.50 (U/mL)	0.69 (U/mL)	12%	9%	104%
SARS-CoV-2 Nucleocapsid	Indirect	1,000 - 1.37 (U/mL)	300 (U/mL)	5.50 (U/mL)	0.69 (U/mL)	9.5%	13%	103%

\*Intra-assay and inter-assay precision are calculated with n=20 and n=10 replicates, respectively.

## Why the nucleocapsid addition?

The ability to measure antibodies towards NP as well as S1 and S2 provides an opportunity to distinguish antibody responses caused by vaccination versus those caused by infection. All currently authorized SARS-CoV-2 functional vaccines, such as the Pfizer and Moderna mRNA vaccines and the Johnson and Johnson DNA vaccine, use the spike glycoprotein as the immunogen

to elicit a protective antibody response in the patient. Thus, detecting antibodies specific for NP in patients that have been vaccinated suggests that they have also been previously infected with SARS-CoV-2. This sort of tool is useful in seroprevalence studies, as well as in studies focused on elucidating the immune responses of vaccinated patients.

SARS-CoV-2 Spike Proteins S1 and S2 IgG Assay vs. Molecular COVID-19 Test		
N = 360	Confirmed Positive	Confirmed Negative
IgG Test Positive	33	0
IgG Test Negative	1	326

SARS-CoV-2 Nucleocapsid IgG Assay vs. Molecular COVID-19 Test		
N = 360	Confirmed Positive	Confirmed Negative
IgG Test Positive	32	19
IgG Test Negative	2	307

	S1 and S2 vs. PCR	Nucleocapsid vs. PCR
Sensitivity (PPA)	97.1%	94.1%
Sensitivity (NPA)	100%	94.2%
Positive Predictive Value (PPV)	100%	62.7%
Negative Predictive Value (NPV)	99.7%	99.4%



**Quansys Biosciences**  
365 North 600 West  
Logan, UT 84321  
www.quansysbio.com

Fax: 435-750-6869  
Phone: 435-752-0531  
Toll Free: 888-QUANSYS (782-6797)



Quansys is an ISO 9001:2015 and ISO 13485:2016 registered company and complies with GMP. Products are designed, developed, and manufactured according to the procedures outlined in our Quality Management System.

©2024 Quansys Biosciences Inc. All rights reserved. Q-View and Q-Plex are Trademarks of Quansys Biosciences Inc. ISO is a trademark of the International Standards Organization. Specifications, terms and pricing are subject to change. Not all products are available in all countries. Please consult your local sales representative for details.